In fact, recent clinical progress with PRMT5 inhibitors such as GSK3326595 and JNJ-64619178 has highlighted their therapeutic potential in molecularly defined subgroups of CRC [31,32,33]. The gene discussed is PRMT5; the disease is colorectal carcinoma.